World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ChiCTR
Last refreshed on: 16 December 2019
Main ID:  ChiCTR1900028152
Date of registration: 2019-12-13
Prospective Registration: Yes
Primary sponsor: Zhongda Hospital Affiliated to Southeast University
Public title: Serum interleukins-6: a predictive biomarker for connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH)
Scientific title: Serum interleukins-6: a predictive biomarker for connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH)
Date of first enrolment: 2020-01-01
Target sample size: Target condition:200;Difficult condition:0
Recruitment status: Pending
URL:  http://www.chictr.org.cn/showproj.aspx?proj=46499
Study type:  Diagnostic test
Study design:  Sequential  
Phase:  N/A
Countries of recruitment
China
Contacts
Name: Yuhan Qin   
Address:  87 Ding-Jia-Qiao, Gulou District, Nanjing, Jiangsu, China
Telephone: +86 15851869029
Email: 986742402@qq.com
Affiliation:  Medical School, Southeast University
Name: Chengchun Tang   
Address:  87 Ding-Jia-Qiao, Gulou District, Nanjing, Jiangsu, China
Telephone: +86 13914705570
Email: tangchengchun@hotmail.com
Affiliation:  Medical School, Southeast University
Key inclusion & exclusion criteria
Inclusion criteria: participants received right heart catheterization examination and were clearly diagnosed as PAH.
Exclusion criteria: Patients were excluded if they have heritable PAH, drugs/toxins induced PAH, idiopathic PAH or PH associated with chronic obstructive pulmonary disease (COPD), obstructive sleep apnea-hypopnea syndrome(OSAHS), chronic thromboembolic pulmonary hypertension (CTEPH), left heart disease, interstitial lung disease.

Age minimum: 18
Age maximum: 80
Gender: Both
Health Condition(s) or Problem(s) studied
pulmonary arterial hypertension
Intervention(s)
Gold Standard:Clinical outcome;Index test:serum IL-6;
Primary Outcome(s)
CTD-PAH;SEN, SPE, ACC, AUC of ROC;
Secondary Outcome(s)
Secondary ID(s)
Source(s) of Monetary Support
own expense
Secondary Sponsor(s)
Ethics review
Status: Not approved
Approval date:
Contact:
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history